DMDavid N. Matlock

David N. Matlock

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David N. Matlock has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Sherry E. Courtney

    University of Arkansas for Medical Sciences in Little Rock Little Rock Arkansas USA

    6 shared publications
  • Christer Sinderby

    Keenan Research Centre for Biomedical Science St. Michael's Hospital Toronto Ontario Canada

    4 shared publications
  • Jennifer Beck

    Keenan Research Centre for Biomedical Science St. Michael's Hospital Toronto Ontario Canada

    3 shared publications
  • Shasha Bai

    Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio

    3 shared publications
  • Chary Akmyradov

    Arkansas Children’s Hospital

    2 shared publications
  • Norman Comtois

    Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada

    2 shared publications

Latest Publications

  • Feasibility of synchronized high flow nasal cannula

    by David N. Matlock, Jennifer Beck, Cong Lu, Danqiong Wang, Victoria L. Winningham, Sherry E. Courtney, Christer Sinderby

    Background: A high‐flow nasal cannula (cHFNC) delivers flow continuously (during inspiration and expiration). Using the diaphragm electrical activity (Edi), synchronizing HFNC could be an alternative (cycling high/low flow on inspiration/expiration, respectively). The objective of this study was to demonstrate the feasibility of synchronized HFNC (sHFNC) and compare it to cHFNC. Methods: Different levels of cHFNC and sHFNC (4, 6, 8, and 10 liters per minute [LPM], with 2 LPM on expiration for sHFNC) were compared in eight rabbits (mean weight 3.16 kg), before and after acute lung injury (pre‐ALI and post‐ALI). Edi, tracheal pressure (Ptr), esophageal pressure (Pes), flow, and arterial CO 2 were measured. In addition to the animal study, one 3.52 kg infant received sHFNC and cHFNC using a Servo‐U ventilator. Results: In the animal study, there were more pronounced decreases in Edi, reduced Pes swings and reduced PaCO 2 at comparable flows during sHFNC compared to cHFNC both pre and post‐ALI ( p < .05). Baseline (pre‐inspiratory) Ptr was 2−7 cmH 2 O greater during cHFNC ( p < .05) indicating more dynamic hyperinflation. In one infant, the ventilator performed as expected, delivering Edi‐synchronized high/low flow. Conclusion: Synchronizing high flow unloaded breathing, decreased Edi, and reduced PaCO 2 in an animal model and is feasible in infants.

  • Open Access

    The Diaphragmatic Initiated Ventilatory Assist (DIVA) trial: study protocol for a randomized controlled trial comparing rates of extubation failure in extremely premature infants undergoing extubation to non-invasive neurally adjusted ventilatory assist versus non-synchronized nasal intermittent positive pressure ventilation

    by David N. Matlock, Sarah J. Ratcliffe, Sherry E. Courtney, Haresh Kirpalani, Kimberly Firestone, Howard Stein, Kevin Dysart, Karen Warren, Mitchell R. Goldstein, Kelli C. Lund, et al.

    Background: Invasive mechanical ventilation contributes to bronchopulmonary dysplasia (BPD), the most common complication of prematurity and the leading respiratory cause of childhood morbidity. Non-invasive ventilation (NIV) may limit invasive ventilation exposure and can be either synchronized or non-synchronized (NS). Pooled data suggest synchronized forms may be superior. Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) delivers NIV synchronized to the neural signal for breathing, which is detected with a specialized catheter. The DIVA (Diaphragmatic Initiated Ventilatory Assist) trial aims to determine in infants born 240/7–276/7 weeks’ gestation undergoing extubation whether NIV-NAVA compared to non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV) reduces the incidence of extubation failure within 5 days of extubation. Methods: This is a prospective, unblinded, pragmatic, multicenter phase III randomized clinical trial. Inclusion criteria are preterm infants 24–276/7 weeks gestational age who were intubated within the first 7 days of life for at least 12 h and are undergoing extubation in the first 28 postnatal days. All sites will enter an initial run-in phase, where all infants are allocated to NIV-NAVA, and an independent technical committee assesses site performance. Subsequently, all enrolled infants are randomized to NIV-NAVA or NS-NIPPV at extubation. The primary outcome is extubation failure within 5 days of extubation, defined as any of the following: (1) rise in FiO2 at least 20% from pre-extubation for > 2 h, (2) pH ≤ 7.20 or pCO2 ≥ 70 mmHg; (3) > 1 apnea requiring positive pressure ventilation (PPV) or ≥ 6 apneas requiring stimulation within 6 h; (4) emergent intubation for cardiovascular instability or surgery. Our sample size of 478 provides 90% power to detect a 15% absolute reduction in the primary outcome. Enrolled infants will be followed for safety and secondary outcomes through 36 weeks’ postmenstrual age, discharge, death, or transfer. Discussion: The DIVA trial is the first large multicenter trial designed to assess the impact of NIV-NAVA on relevant clinical outcomes for preterm infants. The DIVA trial design incorporates input from clinical NAVA experts and includes innovative features, such as a run-in phase, to ensure consistent technical performance across sites. Trial registration: www.ClinicalTrials.gov, trial identifier NCT05446272, registered July 6, 2022.


  • Tidal volume delivery during nasal intermittent positive pressure ventilation: infant cannula vs. nasal continuous positive airway pressure prongs

    by Ashley L. Lynch, David N. Matlock, Chary Akmyradov, Michael D. Weisner, Jennifer Beck, Christer Sinderby, Sherry E. Courtney

    Objective To measure tidal volume delivery during nasal intermittent positive pressure ventilation with two nasal interfaces: infant cannula and nasal prongs. Study design A single-center crossover study of neonates with mild respiratory distress. Fifteen preterm neonates were randomized to initial interface of infant cannula or nasal prongs and monitored on a sequence of pressure settings first on the initial interface, then repeated on the alternate interface. We compared relative tidal volumes between the two interfaces with two-way repeated measures ANOVA during three breath types: synchronized (I), patient effort without ventilator breaths (II), and ventilator breaths without patient effort (III). Clinical trial #NCT04326270. Results Type III breaths delivered no significant tidal volume. No significant difference was measured in relative tidal volume delivery between the interfaces when breath types were matched. Conclusions Nasal intermittent positive pressure ventilation delivers neither clinically nor statistically significant tidal volume with either infant cannula or nasal prongs.


  • The effect of bethanechol on tracheobronchomalacia in preterm infants with bronchopulmonary dysplasia: a retrospective cohort study

    by C. Preston Pugh, Chary Akmyradov, Sherry E. Courtney, Amit Agarwal, Angela Chandler, David N. Matlock

    Objective Bethanechol has demonstrated improvement in trachealis tone in animal models, but no trials have studied efficacy in infants. This study aimed to examine if bethanechol improves a standardized pulmonary severity score (PSS) in infants with severe bronchopulmonary dysplasia with a diagnosis of tracheobronchomalacia (TBM). Study design This retrospective cohort study evaluated cases treated with bethanechol matched with controls who did not receive bethanechol. TBM was diagnosed by dynamic computography. Daily PSS was recorded for each infant from 40 to 55 weeks post-menstrual age. Results Cases’ mean PSS change was 21% lower than the controls’ mean PSS change pre- and post-bethanechol (95% CI −40%, −2%) by paired t-test (p = 0.03). Matched differences (controls’ PSS – cases’ PSS) demonstrated greater mean PSS difference post-bethanechol compared to pre-bethanechol 0.17, (95% CI 0.05, 0.29) by paired t-test (p = 0.009). Conclusion Infants with TBM treated with bethanechol compared to those not treated had a lower PSS reflecting improved respiratory status.


  • Ventilatory Strategies in Infants with Established Severe Bronchopulmonary Dysplasia: A Multicenter Point Prevalence Study

    by Robin L. McKinney, Natalie Napolitano, Jonathan J. Levin, Matthew J. Kielt, Steven H. Abman, Milenka Cuevas Guaman, Rebecca S. Rose, Sherry E. Courtney, David Matlock, Amit Agarwal, et al.


  • Implementing a Weaning Protocol for Noninvasive Respiratory Support in Neonates Decreases Overuse and , Length of Stay

    by David N Matlock, Sarah M Perez, Heather A Borchert, Betty L Proffitt, Sara E Peeples, Angela L Chandler, Sherry E Courtney, Shasha Bai, Ashley S Ross

    BACKGROUND: As part of efforts to decrease length of hospital stay, a protocol for weaning noninvasive respiratory support was implemented using quality improvement methodology. The objective of this study was to determine whether protocol implementation decreased the time to wean to no respiratory support by 24 h (30% reduction) over 3 months in preterm infants 30–34 weeks gestational age. METHODS: A quality improvement project was conducted with the following outcome measures: primary outcome measured was hours to wean; secondary outcomes included duration of respiratory support, length of stay, and postmenstrual age at feeding milestones; and balance measures were duration of oxygen exposure and growth velocity. RESULTS: Data from 89 subjects were included. Following implementation, decreases were seen in time to wean (40% reduction, P < .001), length of stay (25% reduction, P = .02), and growth velocity (21% reduction, P = .02). CONCLUSIONS: Implementing a weaning protocol decreases duration of support and length of stay in infants 30–34 weeks gestational age. Weaning respiratory support more quickly may decrease growth velocity.


  • Work of Breathing in Premature Neonates: Noninvasive Neurally-Adjusted Ventilatory Assist versus Noninvasive Ventilation

    by David N Matlock, Shasha Bai, Michael D Weisner, Norman Comtois, Jennifer Beck, Christer Sinderby, Sherry E Courtney

    BACKGROUND: We tested whether work of breathing in premature newborns estimated by phase angle (θ) by using respiratory inductance plethysmography is decreased during neurally-adjusted ventilatory assist (NAVA) noninvasive ventilation (NIV) versus NIV alone. METHODS: NAVA NIV and NIV were applied in random order while using respiratory inductance plethysmography to measure the phase angle. RESULTS: Patient-ventilator asynchrony was decreased during NAVA NIV; however, the phase angle was not different between the modes. A large number of repeated assists with switches to backup were found when using NAVA NIV. Results of the analysis indicated these were due to the apnea alarm limit set during NAVA NIV. CONCLUSIONS: The improvement in patient-ventilator synchrony supports the hypothesis that work of breathing may be decreased with NAVA NIV; however, we were unable to demonstrate this with our study design. Short apnea time settings with NAVA NIV led to a large number of switches to backup and repeated assists during the same neural effort. (ClinicalTrials.gov registration NCT02788110.)


  • Tidal volume transmission during non-synchronized nasal intermittent positive pressure ventilation via RAM® cannula

    by David N. Matlock, Shasha Bai, Michael D. Weisner, Norman Comtois, Jennifer Beck, Christer Sinderby, Sherry E. Courtney

    Nasal intermittent positive pressure ventilation (NIPPV) is a widely used mode of support in neonates, during which ventilator inflations may or may not coincide with spontaneous breathing. We tested the hypothesis that inflations delivered with NIPPV via RAM® cannula and not accompanied by patient effort produce minimal tidal volume as measured by respiratory inductance plethysmography. Fourteen subjects were monitored while receiving NIPPV. We compared tidal volumes during ventilator-supported breaths, unsupported breaths, and ventilator inflations not accompanied by patient effort (defined using electrical activity of the diaphragm). Mean tidal volumes in arbitrary units were 0.30 ± 0.22 in NIPPV inflations associated with patient effort and 0.27 ± 0.15 in spontaneous breaths without ventilator assistance (p = 0.82). Tidal volumes during ventilator-only inflations were 0.06 ± 0.04 (p < 0.005 vs. both ventilator-assisted and unassisted efforts). NIPPV via RAM cannula produces minimal, clinically insignificant tidal volumes during non-spontaneous inflations.